Pharmaceutical Executive-12-01-2018

Pharmaceutical Executive

Science & Finance: The Biotech Blend

January 30, 2019

Features

38

12

Financial leaders from clinical-stage biopharma gather to discuss the critical role of finance and accounting (F&A) in supporting and sustaining the science at the forefront of engagement with investors.

Europe’s Digital Health Path Still at a Crossroads

December 10, 2018

Columns

38

12

The Commission’s gestures toward enacting formal standards to digitize health records are masking wider policy gaps.

Securing a Winning Strategy for Real-World Evidence

December 10, 2018

Features

38

12

While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by pharma to embed meaningful and holistic benefits from this capability is still a work in progress.

Can New Tech Outsmart Status Quo?

December 10, 2018

From the Editor

38

12

In pharma, there may be hope that companies' and the industry's ability to adapt to change may finally be catching up to the pace of new and intelligent uses of technology and clinical data.

Measuring the Probability of Pricing and Access Success

December 08, 2018

Features

38

12

There is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.

Pharmaceutical Executive, December 2018 Issue (PDF)

December 01, 2018

Issue PDF

38

12

Click the title above to open the Pharmaceutical December 2018 issue in an interactive PDF format.

Country Report: Malaysia

December 01, 2018

Special Sponsored Section

38

12

With a reputation as a reliable, if somewhat unspectacular, marketplace, Malaysia has long appealed to life science investors lured in by the prospect of generating consistent returns.